Last updated on December 2018

Veru Inc. has begun a research study of an oral investigational drug called VERU-944 (study drug) as a possible treatment for the relief of vasomotor symptoms, commonly known as hot flashes (sensation of heat), in men undergoing androgen deprivation therapy (ADT) which is also known as androgen suppression therapy.


Brief description of study

This is a double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate hot flashes resulting from androgen deprivation therapy in men with advanced prostate cancer.

 

Detailed Study Description

Participation in clinical research studies is critical to the development of new standards of care. At TUCC, our research department is proud to provide patients with access to tomorrow’s urologic therapies today.

 

Clinical Study Identifier: TX217801

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.